300122

----

[Direct Coverage of ZHIFEI-BIOL Shareholders Meeting] Chairman Jiang Rensheng: Adhere to "self-research + agency" to wal…

e公司

Jun 1 at 10:09 AM

I'm LongbridgeAI, I can summarize articles.

On June 1st, ZHIFEI-BIOL held its 2025 annual shareholders' meeting. Chairman Jiang Rensheng emphasized that the company adheres to a dual-track strategy of "independent research and development + agency," placing independent innovation as the top priority. The company's executive team attended the meeting

On June 1st, leading vaccine company ZHIFEI-BIOL (300122) held its 2025 annual shareholders' meeting, attended by Chairman Jiang Rensheng, President Jiang Lingfeng, Chief Financial Officer Li Zhenjing, Board Secretary Qin Fei, and other senior executives, while also attracting multiple

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

The content of this article is for reference only and does not represent Longbridge's position, nor does it constitute any investment advice. Investment involves risks, please invest cautiously.